Palbociclib and Binimetinib in Advanced Triple Negative Breast Cancer
Status:
Recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
This study is an interventional, prospective, multicentric, single-arm, open label, phase Ib
clinical trial. This study will be carried out in patients diagnosed of metastatic or locally
advanced unresectable triple negative breast cancer with activation of ERK and/or CDK4/6 in
which the following will be assesed: the overall response rate, the aggregation of antitumor
effect depending on the different kinome profiles and the safety profile to the combination
of palbociclib and binimetinib.